Sector News

Chinese buyer resurrects US Boehringer plant

November 3, 2014
Life sciences
Chinese company UniTao has agreed to buy a Boehringer Ingelheim manufacturing site in Petersburg, US, which was scheduled to be closed by the end of the year with the loss of 240 jobs.
 
UniTao will use the active pharmaceutical ingredient (API) manufacturing facility site to make APIs for global distribution, and intends to employ up to 376 people. The company has indicated that the availability of a skilled workforce was a favourable factor in its decision to buy the site.
 
By Phillip Broadwith
 

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach